---
title: "DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven"
description: "DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ..."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255313967.md"
published_at: "2025-08-30T13:36:39.000Z"
---

# DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven

> DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ...

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ...

### Related Stocks

- [BHVN.US - Biohaven Pharmaceutical](https://longbridge.com/en/quote/BHVN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Biohaven highlights degrader platforms in new investor presentation | Biohaven Ltd. (BHVN) announced an investor presentation on January 12, 2026, detailing advancements in its drug developm | [Link](https://longbridge.com/en/news/272300228.md) |
| Biohaven Ltd Announces Investor Presentation on January 12, 2026 | Biohaven Ltd will hold an investor presentation on January 12, 2026, showcasing its novel degrader platform for autoimmu | [Link](https://longbridge.com/en/news/272297879.md) |
| Biohaven reports Phase II BHV-7000 trial results for MDD | Biohaven announced Phase II trial results for BHV-7000 in MDD, showing no primary endpoint achievement but trends favori | [Link](https://longbridge.com/en/news/270844475.md) |
| Biohaven Misses The Mark In Depression Trial, Stock Falls | Biohaven's Phase 2 study with BHV-7000 for major depressive disorder did not meet its primary endpoint, leading to a 15. | [Link](https://longbridge.com/en/news/270854796.md) |
| Biohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors | Biohaven Ltd. announced promising Phase 1 trial results for BHV-1510 combined with cemiplimab in advanced solid tumors.  | [Link](https://longbridge.com/en/news/269376483.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.